Talis Biomedical Corporation (TLIS)

$0.835

+0.02 (+2.83%)
Rating:
Recommendation:
-
Symbol TLIS
Price $0.835
Beta 0.000
Volume Avg. 0.18M
Market Cap 22.227M
Shares () -
52 Week Range 0.8-12.88
1y Target Est -
DCF Unlevered TLIS DCF ->
DCF Levered TLIS LDCF ->
ROE -51.02% Strong Sell
ROA -54.72% Strong Sell
Operating Margin -
Debt / Equity 13.71% Neutral
P/E -
P/B 0.11 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest TLIS news


Mr. Brian Coe M.B.A.
Healthcare
Medical Devices
NASDAQ Global Market

Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.